Advertisement

Hepatitis C: More Results From Sofosbuvir/Ledipasvir & ABT-450/r Combo Trials — Physician’s First Watch

Medical News |
April 14, 2014

Hepatitis C: More Results From Sofosbuvir/Ledipasvir & ABT-450/r Combo Trials

By Joe Elia

Further presentations from a London liver conference show that hepatitis C is on the run, but the question is, at what cost?

In studies appearing in the New England Journal of Medicine, a single-pill formulation of sofosbuvir plus ledipasvir (shown in other NEJM studies last week to be roughly 95% effective in cirrhosis-free patients) was equally effective among previously untreated as well as previously treated patients, many with cirrhosis.

Similarly, a regimen centered around the protease inhibitor ABT-450 produced at least a 90% sustained virologic response in previously untreated and previously treated patients with compensated cirrhosis.

Editorialists write that previous medical barriers to hepatitis C treatment "may now largely disappear," but that costs are another barrier. Indeed, back-of-the-envelope calculations show the cost to treat the estimated 3.2 million U.S. cases with a 12-week, $84,000 course of sofosbuvir alone (without ledipasvir) comes to roughly $250 billion.

Reader Comments (1)

Dr Mary Tuttle, DNP Other Healthcare Professional, Family Medicine/General Practice, Community clinic

What about the side effects of treatment -and the fact that only 20-30% respond?? I have had people die from rare anemias from the "new" HCV treatments.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement